Hemab Therapeutics Closes $157M Series C Led by Sofinnova Partners

Deal Summary

Hemab Therapeutics, a clinical-stage biotech focused on prophylactic treatments for bleeding and thrombotic disorders, raised $157M in a Series C financing. The round was led by Sofinnova Partners with participation from a large long-only global asset management company and additional new investors.